Thermogenesis raises $6.67M in a private placement Thermogenesis announced that it has entered into definitive agreements with institutional investors in connection with a private placement of common stock and warrants to purchase common stock. Upon the closing of this financing, ThermoGenesis will receive gross proceeds of approximately $6.67 million resulting from the issuance and sale of approximately 3.33M shares of common stock at a price per share of $2.00. The purchasers will also receive warrants to purchase up to approximately 1.66M shares of common stock at an exercise price of $2.81 per share. The warrants are non-exercisable for six months after the closing of the financing and have a term of 5 years.
Texas Stem Cell to use Cesca's AutoXpress AXP technology Cesca Therapeutics announced that Texas Stem Cell has committed to utilizing Cesca's AutoXpress AXP technology for its cord blood banking business. The AXP platform includes a 'smart' processing device and sterile disposable that automatically concentrates the stem cells from a cord blood unit in less than one hour and delivers them directly into Cesca's patented sample bag which is optimized for cryopreservation and storage.